Evidence map›Paper›PMID 35580533›Full record

ArticleThe International journal on drug policy2022

Impact of COVID-19 on substance use disorder treatment services in Kenya: Qualitative findings from healthcare providers.

Abbe Muller, Matthew J Akiyama, Lindsey Riback, Mercy Nyakowa, Helgar Musyoki, Peter Cherutich, Ann Kurth

Abstract read
In one paragraph

Article in The International journal on drug policy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Abbe MullerBoston University School of Medicine, Boston, Massachusetts, USA. Electronic address: abbe.muller@gmail.com.
Matthew J AkiyamaAlbert Einstein College of Medicine / Montefiore Medical Center, Bronx, New York, USA.
Lindsey RibackAlbert Einstein College of Medicine / Montefiore Medical Center, Bronx, New York, USA.
Mercy NyakowaKenya Ministry of Health, National AIDS & STI Control Program (NASCOP), Nairobi, Kenya.
Helgar MusyokiKenya Ministry of Health, National AIDS & STI Control Program (NASCOP), Nairobi, Kenya.
Peter CherutichKenya Ministry of Health, National AIDS & STI Control Program (NASCOP), Nairobi, Kenya.
Ann KurthYale University School of Nursing, Orange CT.

Funding

Test and Linkage to Care (TLC_IDU) KenyaR01DA032080 · NIDA · YALE UNIVERSITY · PI CHERUTICH, PETER KIPKOECH, KURTH, ANN ELIZABETH · 2011 to 2015
$4.1M
Leveraging HCV Phylogenetic Networks to Prevent HIV and Other Blood Borne Infections Among People Who Inject DrugsDP2DA053730 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI AKIYAMA, MATTHEW · 2021 to 2021
$2.5M
Advance Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants LivingR00DA043011 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI AKIYAMA, MATTHEW · 2020 to 2022
$747k
NIDA NIH HHS DP2 DA053730NIDA NIH HHS R00 DA043011NIDA NIH HHS R01 DA032080
6 · The paper itself

Abstract

backgroundPeople who inject drugs are at an increased risk for contracting SARS-CoV-2 and have experienced barriers to accessing harm reduction services during the COVID-19 pandemic. Understanding how to best provide these services is essential for COVID-19 mitigation. The goal of this study was to ascertain challenges and successes for caring for people who inject drugs in Kenya during the COVID-19 pandemic.

methodsWe conducted focus group discussions and one-on-one key informant interviews with healthcare providers who work with people who inject drugs in Kenya. Interviews explored how COVID-19 and social distancing measures impacted service provision, as well as what strategies were used to overcome these barriers. We used thematic analysis to analyze transcribed interviews.

resultsParticipants included 29 service providers from 11 healthcare professions at three medication assisted treatment (MAT) and four drop-in center (DIC) sites (N=15 males and N=14 females, with an average age of 35 years). Four overarching themes emerged in our thematic analysis in which providers described both barriers to providing care and solutions to overcome them: (1) COVID-19-related misconceptions; (2) Limited COVID-19 testing and screening; (3) Structural changes related to service provision; and (4) Access to material resources such as meals, needle and syringe program kits, and personal protective equipment.

conclusionsOur findings demonstrate the COVID-19 pandemic-imposed challenges for substance use disorder treatment providers and patients, however with ingenuity many of these challenges were able to be overcome.

Indexed as

COVID-19HIV InfectionsSubstance Abuse, IntravenousAdultCOVID-19 TestingFemaleHealth PersonnelHumansKenyaMalePandemicsSARS-CoV-2COVID-19Injection drug useLMICPeople who inject drugsPolicySubstance use disorder services

Identifiers

PMID35580533
PMCPMC9106529

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.